Amotiv Limited (AOV : TSX)
Common Stock
$9.84
CAD
-0.01 (-0.10%)
Last updated: 2026-07-02
AOV
Amotiv Limited
WealthAwesomePerformance
1 Day
-0.10%
1 Week
+5.02%
1 Month
+20.00%
YTD
+66.50%
Key Statistics
Market Cap
$576.83M
52W High
$9.98
52W Low
$5.66
P/E Ratio
-
50 Day MA
$5.81
200 Day MA
$5.36
Beta
0.49
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/2/2026 | $9.84 | $9.91 | $9.69 | $9.84 | $9.84 | 274,622 |
| 6/30/2026 | $9.79 | $9.91 | $9.62 | $9.85 | $9.85 | 183,562 |
| 6/29/2026 | $9.47 | $9.98 | $9.45 | $9.70 | $9.70 | 148,001 |
| 6/26/2026 | $9.33 | $9.45 | $9.29 | $9.45 | $9.45 | 33,983 |
| 6/25/2026 | $9.16 | $9.44 | $9.16 | $9.37 | $9.37 | 24,667 |
| 6/24/2026 | $9.22 | $9.39 | $9.22 | $9.35 | $9.35 | 25,200 |
| 6/23/2026 | $9.30 | $9.34 | $9.00 | $9.23 | $9.23 | 44,131 |
| 6/22/2026 | $9.46 | $9.46 | $9.28 | $9.31 | $9.31 | 70,141 |
| 6/19/2026 | $9.02 | $9.38 | $9.02 | $9.27 | $9.27 | 38,037 |
| 6/18/2026 | $9.32 | $9.47 | $9.27 | $9.32 | $9.32 | 112,231 |
Analyst Price Targets
Based on analyst covering AOV
Wall Street analysts forecast AOV stock price to fall 26.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.19
-26.9% Upside
Current Price
C$9.84
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AOV's historical volatility
30-Day Vol
25.6%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.76
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.44 | C$9.56 โ C$11.41 |
| 60 trading days | C$11.08 | C$9.78 โ C$12.56 |
| 90 trading days | C$11.76 | C$10.10 โ C$13.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Financials
- Revenue (TTM)
- $332.21M
- EBITDA
- $49.78M
- Profit Margin
- -5.25%
- ROE (TTM)
- -2.21%
- EPS (Diluted)
- -0.16
- Book Value
- 7.53
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE Report